Você pesquisou por y - Critical Care Science (CCS)
You searched for:"Luiz Eduardo Fonteles Ritt"
We found (2) results for your search.Abstract
Rev Bras Ter Intensiva. 2008;20(2):165-172
DOI 10.1590/S0103-507X2008000200009
BACKGROUND AND OBJECTIVES: Acute coronary syndromes (ACS) are one of the most common causes of ICU admissions. New drugs have been developed for management of ACS. These drugs reduced morbidity and mortality; however their adverse effects or their incorrect use may cause excessive bleeding. The objective of this review is to present the principal peculiarities, doses, and indications of these drugs in ACS settings. METHODS: Original articles were retrieved crossing the terms acute coronary syndromes and antithrombotic therapy in the MedLine database as well as search for Brazilian and international guidelines in http://sumsearch.uthscsa.edu. RESULTS: In the treatment of acute coronary syndromes with non-ST-segment elevation enoxaparin was as efficient as UFH, but with a simpler management (SYNERGY and A to Z studies). In this same setting, fondaparinux was non inferior to enoxaparin and had lesser bleedings (OASIS 5), bivalirudin, combined or not with GPIIbIIIa blockers, was not inferior when compared with other heparins (ACUITY). In ST-segment elevation ACS, enoxaparin was superior to HNF in patients treated with fibrinolysis (EXTRACT TIMI 25); in OASIS 6 fondaparinux was superior to UFH in patients treated with thrombolytic therapy and not submitted to reperfusion. CONCLUSIONS: The correct management and individual combination of antithrombotic drugs are mandatory for decreased mortality and of major cardiovascular events, reducing the undesirable risk of additional bleeding.
Abstract
Rev Bras Ter Intensiva. 2008;20(2):165-172
DOI 10.1590/S0103-507X2008000200009
BACKGROUND AND OBJECTIVES: Acute coronary syndromes (ACS) are one of the most common causes of ICU admissions. New drugs have been developed for management of ACS. These drugs reduced morbidity and mortality; however their adverse effects or their incorrect use may cause excessive bleeding. The objective of this review is to present the principal peculiarities, doses, and indications of these drugs in ACS settings. METHODS: Original articles were retrieved crossing the terms acute coronary syndromes and antithrombotic therapy in the MedLine database as well as search for Brazilian and international guidelines in http://sumsearch.uthscsa.edu. RESULTS: In the treatment of acute coronary syndromes with non-ST-segment elevation enoxaparin was as efficient as UFH, but with a simpler management (SYNERGY and A to Z studies). In this same setting, fondaparinux was non inferior to enoxaparin and had lesser bleedings (OASIS 5), bivalirudin, combined or not with GPIIbIIIa blockers, was not inferior when compared with other heparins (ACUITY). In ST-segment elevation ACS, enoxaparin was superior to HNF in patients treated with fibrinolysis (EXTRACT TIMI 25); in OASIS 6 fondaparinux was superior to UFH in patients treated with thrombolytic therapy and not submitted to reperfusion. CONCLUSIONS: The correct management and individual combination of antithrombotic drugs are mandatory for decreased mortality and of major cardiovascular events, reducing the undesirable risk of additional bleeding.
Abstract
Rev Bras Ter Intensiva. 2006;18(4):402-406
DOI 10.1590/S0103-507X2006000400014
BACKGROUND AND OBJECTIVES: Sepsis is a syndrome with an important inflammatory component in its pathophysiology. Some drugs that act on the activation of inflammatory cascade have been tested in septic patients. Statins, beyond hypolipemic effects, have anti-inflammatory capacities, known as pleiotropic effects. That action may be of value on sepsis treatment. Review of publications who discuss the use of statins. This article has the objective to review the mainly papers about statins and sepses. METHODS: Original published articles were searched using Medline database crossing the keys words "sepsis and statins" between 1990 and 2006 RESULTS: Experimental and retrospective studies has been investigated the use of statins in septic patients, until this moment, most of then show benefits on morbidity and mortality. However, there is not prospective, randomized, placebo controlled trials. Or metanalyses, witch denotes lack strong and robust that could be indicated this action. So, since the benefit is still unable, it is necessary randomized clinical trials witch can prove this theory. CONCLUSIONS: Several experimental and retrospective studies have investigated the use of statins in septic patients, but despite literature demonstrating a promising role for its use in these patients, these studies are experimental or retrospective. Therefore, we must wait larger, prospective, randomized trials before we may be able to understand its role and possibly recommend these drugs in the treatment of septic patients.
Abstract
Rev Bras Ter Intensiva. 2006;18(4):402-406
DOI 10.1590/S0103-507X2006000400014
BACKGROUND AND OBJECTIVES: Sepsis is a syndrome with an important inflammatory component in its pathophysiology. Some drugs that act on the activation of inflammatory cascade have been tested in septic patients. Statins, beyond hypolipemic effects, have anti-inflammatory capacities, known as pleiotropic effects. That action may be of value on sepsis treatment. Review of publications who discuss the use of statins. This article has the objective to review the mainly papers about statins and sepses. METHODS: Original published articles were searched using Medline database crossing the keys words "sepsis and statins" between 1990 and 2006 RESULTS: Experimental and retrospective studies has been investigated the use of statins in septic patients, until this moment, most of then show benefits on morbidity and mortality. However, there is not prospective, randomized, placebo controlled trials. Or metanalyses, witch denotes lack strong and robust that could be indicated this action. So, since the benefit is still unable, it is necessary randomized clinical trials witch can prove this theory. CONCLUSIONS: Several experimental and retrospective studies have investigated the use of statins in septic patients, but despite literature demonstrating a promising role for its use in these patients, these studies are experimental or retrospective. Therefore, we must wait larger, prospective, randomized trials before we may be able to understand its role and possibly recommend these drugs in the treatment of septic patients.